Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura

NICE technology appraisals [TA205] Published date:

1 Guidance

1 Guidance

1.1 Eltrombopag is not recommended within its marketing authorisation for the treatment of chronic immune (idiopathic) thrombocytopenic purpura:

  • in splenectomised adults whose condition is refractory to other treatments (for example, corticosteroids, immunoglobulins) or

  • as second-line treatment in non-splenectomised adults where surgery is contraindicated.

1.2 People currently receiving eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura should have the option to continue treatment until they and their clinician consider it appropriate to stop.

NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce technology appraisals guidance. Accreditation is valid for 5 years from September 2009 and applies to guidance produced since June 2008 using the processes described in NICE's 'The guide to the methods of technology appraisal' (2008). More information on accreditation can be viewed at www.nice.org.uk/accreditation
Get involved